Chung‐Wei Su

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma

Chung‐Wei Su, Wei Teng, Po‐Ting Lin et al. · Cancer Medicine · 2022 · 33 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma

Chung‐Wei Su, Wei Teng, Eric Yi-Liang Shen et al. · The Oncologist · 2024 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis

Wen‐Juei Jeng, Rong‐Nan Chien, Yi‐Cheng Chen et al. · Hepatology · 2023 · 27 citations

Medicine, Oncology, Pharmacotherapy +17

Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.

Chung‐Wei Su, Ming‐Mo Hou, Pei‐Wei Huang et al. · PubMed · 2022 · 19 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in HCC

Chien‐Hao Huang, Wei-Ting Ku, Jayashri Mahalingam et al. · Hepatology · 2025 · 10 citations

Life Sciences, Immunology, Oncology +17